In glioblastoma cells representing another hard-to-treat cancer type, siRNA-mediated or CRISPR/Cas9-mediated inhibition of SRSF3 has been shown to suppress their tumorigenic phenotypes (12,13). This evidence concerns the gene SRSF3 and cancer.